Challenging ourselves to improve the lives of others
We exist to develop therapies that offer the potential to improve outcomes for women living with cancer. We approach these goals with a single-minded focus.
At Olema Oncology, we leverage our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, to achieve our goal of transforming the standard of care for women living with cancer by focusing on developing more convenient and effective therapies.
Join us as we aim to design therapies for improving lives.
For more information, visit the Investors & Media section of our website.
For more information, visit the Investors & Media section of our website.
Our novel approach to advancing breast cancer therapy
Many forms and stages of cancer continue to elude control. Malignant cells adapt and exploit mutations and redundancies, so partial targeting leaves vulnerabilities.
At Olema, we have no patience for incomplete efforts, so we’re developing palazestrant (OP-1250), an orally bioavailable Complete Estrogen Receptor Antagonist, or CERAN, and selective ER degrader, or SERD, for the treatment of ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.